Core Points - The document outlines the management system for the shares held by directors and senior management of Shanghai MicroPort MedBot (Group) Co., Ltd, aiming to enhance market order and protect investors' rights [1][2] - The system is based on relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China, as well as the rules of the Shanghai Stock Exchange [1][2] Summary by Sections General Principles - The system applies to all shares held by directors and senior management, including those in multiple accounts, and mandates compliance with insider trading regulations [2] - Prior to trading, directors and senior management must notify the board secretary in writing, who will verify the company's disclosure status [2][3] Prohibited Trading Activities - Directors and senior management are prohibited from transferring shares under specific conditions, such as within one year of the company's stock listing or within six months after leaving the company [3][4] - Trading is also restricted during certain periods, such as before the announcement of annual or quarterly reports [3][4] Information Reporting and Disclosure - Directors and senior management must report their shareholdings and any changes within two trading days through the Shanghai Stock Exchange [5][6] - The company is responsible for ensuring the accuracy and timeliness of these disclosures [5][6] Share and Account Management - Directors and senior management can only transfer up to 25% of their shares annually, with exceptions for certain legal circumstances [7][8] - New shares acquired through various means are subject to specific transfer conditions [7][8] Responsibilities and Penalties - Violations of the trading rules may result in penalties from regulatory bodies, and the company can impose internal disciplinary actions [9][10] - The company must report any illegal trading activities to the relevant authorities [10] Miscellaneous - The system will be executed in accordance with current laws and regulations, and the board of directors holds the interpretation rights [11]
心脉医疗: 心脉医疗:董事和高级管理人员所持本公司股份及其变动管理制度(2025年8月修订)